- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Outlook “Gloomy” for TB Investment
The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) - at the time the first TB drug approval in 40 years - “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) - at the time the first TB drug approval in 40 years - “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
AstraZeneca’s decision in January to close a laboratory in India that was conducting early-stage research into TB is more typical of Big Pharma’s current approach to TB, says Ward.
TB is “particularly unattractive as a commercial proposition” because of its heavy concentration in poorer countries.
J&J is not expected to profit from bedaquiline, but the company has been “rewarded” by U.S. regulators for developing the TB treatment with a scheme enabling it to put a potentially more lucrative new drug through an accelerated review process.
Although, Ward points out, Japan’s Otsuka has also since won provisional approval in Europe for its delamanid treatment for MDR-TB, few in Big Pharma are following the example of these companies.
http://www.ft.com/cms/s/0/417dee98-a52a-11e3-8988-00144feab7de.html#axzz2wyWoEh2V
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
